Afatinib and Pembrolizumab for Head and Neck Squamous Cell Carcinoma (ALPHA Study)
The primary objectives of the trial is to examine the toxicities and efficacies of afatinib and pembrolizumab for recurrent and/or metastatic head and neck squamous cell carcinoma.
Head and Neck Neoplasms
DRUG: Afatinib Oral Tablet|DRUG: Pembrolizumab Injection
Objective response rate, The objective response rate will be measured by RECIST 1.1., 2 years
Overall survival, Overall survival: from the start of study treatment, to the time of death Progression free survival: from the start of study treatment, to the time of disease progression (RECIST 1.1) or death., 2 years|Toxicities, CTCAE 4.0, Grade 3 or higher, 2 years
It is a single arm, phase II, single center, prospective, open label clinical trial.